Methylation marker for assisting detection of lung cancer
By using a combination of methylation markers from the AHDC1, RASSF1A, SEPTIN9, SDC2, and ZNF304 gene regions, combined with methylation-based quantitative PCR, we achieved high-sensitivity and high-specificity early detection of lung cancer, solving the problems of accuracy and speed in existing lung cancer detection technologies.
Patent Information
- Application Number
- CN202411158039.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-08-21
Smart Images

Figure CN118957072A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of molecular biology detection, specifically, to the field of lung cancer detection, and more specifically, to the detection of methylation levels of lung cancer gene markers. Background Art
[0002] Lung cancer is one of the most common cancers in the world and one of the leading causes of cancer-related death. The 5-year survival rate of lung cancer is less than 20%, only 6% for patients in the advanced stage, and 85% for stage IA. Therefore, early detection of lung cancer is an important means to improve the survival rate of lung cancer.
[0003] The progress of epigenetic research on lung cancer has far-reaching significance for the early diagnosis and treatment of lung cancer. There is evidence that hypermethylation of CpG islands in the promoter of tumor suppressor genes is an important mechanism of gene inactivation. Transcriptional inactivation of different genes will affect the cell cycle, DNA repair, apoptosis, etc., and is closely related to the occurrence and development of cancer. Gene methylation refers to the process in which cytosine (C) in CpG dinucleosides on DNA molecules selectively adds methyl groups to form 5'-methylcytosine under the action of enzymes. In lung cancer patients, CpG island methylation in gene promoter regions is a relatively common phenomenon. Clinically, it is believed that the detection of methylated gene markers in tissue cells and body fluids (such as sputum, serum and plasma) of lung cancer patients is an effective auxiliary detection method for lung cancer, which has the value of improving the detection rate of lung cancer. Studies have shown that DNA methylation can be detected in the sputum of patients 3 years before the diagnosis of lung cancer. If it is combined with cytopathological detection, it can greatly improve the efficiency of lung cancer diagnosis, shorten the detection cycle, and improve the accuracy of diagnosis.
[0004] Currently, the lung cancer methylation detection products approved in China include Transgene's human SHOX2 and RASSF1A gene methylation DNA detection kit (PCR fluorescence method), but the selectivity is still limited and the accuracy needs to be improved. Therefore, this field is in urgent need of a non-invasive, rapid and more accurate lung cancer screening product to provide technical support for improving the effectiveness of lung cancer screening. Summary of the invention
[0005] In view of this, the present invention provides a methylation marker combination for assisting the detection of lung cancer, comprising: a region in the AHDC1 gene as shown in SEQ ID NO: 1.
[0006] The sensitivity, specificity and AUC of the markers of the present invention for lung cancer detection are 88.49%, 91.43% and 0.936 respectively. The present invention can detect lung cancer clinically with fewer markers, saving both cost and time, and can detect patients who are really at risk of lung cancer malignancy at the early stage of the canceration process with high sensitivity and high specificity.
[0007] Furthermore, the methylation marker combination also includes at least one of the following regions:
[0008] The region of the RASSF1A gene as shown in SEQ ID NO:2;
[0009] The region of the SEPTIN9 gene as shown in SEQ ID NO:3;
[0010] The region of the SDC2 gene as shown in SEQ ID NO:4; or
[0011] The region of the ZNF304 gene as shown in SEQ ID NO:5.
[0012] In some specific embodiments, the methylation marker combination is:
[0013] the region of the AHDC1 gene as shown in SEQ ID NO: 1, and the region of the RASSF1A gene as shown in SEQ ID NO: 2;
[0014] the region of the AHDC1 gene as shown in SEQ ID NO: 1, and the region of the SEPTIN9 gene as shown in SEQ ID NO: 3;
[0015] the region of the AHDC1 gene as shown in SEQ ID NO: 1, the region of the SEPTIN9 gene as shown in SEQ ID NO: 3, and the region of the ZNF304 gene as shown in SEQ ID NO: 5;
[0016] The region of the AHDC1 gene as shown in SEQ ID NO: 1, and the region of the SDC2 gene as shown in SEQ ID NO: 4; or
[0017] The region of the AHDC1 gene as shown in SEQ ID NO: 1, and the region of the ZNF304 gene as shown in SEQ ID NO: 5.
[0018] Further, a detection composition for assisting the detection of lung cancer, the composition comprising a detection agent for detecting the methylation level in the following regions:
[0019] The region of the AHDC1 gene as shown in SEQ ID NO: 1.
[0020] Further, the composition may also include at least one of the detection reagents for detecting the methylation level in the following regions:
[0021] The region of the RASSF1A gene as shown in SEQ ID NO:2;
[0022] The region of the SEPTIN9 gene as shown in SEQ ID NO:3;
[0023] The region of the SDC2 gene as shown in SEQ ID NO:4; or
[0024] The region of the ZNF304 gene as shown in SEQ ID NO:5.
[0025] In some specific embodiments, the composition includes a detection reagent for detecting the methylation level in the following regions:
[0026] The region of the AHDC1 gene as shown in SEQ ID NO: 1, and the region of the RASSF1A gene as shown in SEQ ID NO: 2.
[0027] In some specific embodiments, the composition includes a detection reagent for detecting the methylation level in the following regions:
[0028] The region of the AHDC1 gene as shown in SEQ ID NO: 1, and the region of the SEPTIN9 gene as shown in SEQ ID NO: 3.
[0029] In some specific embodiments, the composition includes a detection reagent for detecting the methylation level in the following regions:
[0030] The region of the AHDC1 gene as shown in SEQ ID NO: 1, the region of the SEPTIN9 gene as shown in SEQ ID NO: 3, and the region of the ZNF304 gene as shown in SEQ ID NO: 5.
[0031] In some specific embodiments, the composition includes a detection reagent for detecting the methylation level in the following regions:
[0032] The region of the AHDC1 gene as shown in SEQ ID NO: 1, and the region of the SDC2 gene as shown in SEQ ID NO: 4.
[0033] In some specific embodiments, the composition includes a detection reagent for detecting the methylation level in the following regions:
[0034] The region of the AHDC1 gene as shown in SEQ ID NO: 1, and the region of the ZNF304 gene as shown in SEQ ID NO: 5.
[0035] The region shown in SEQ ID NO: 1 in the AHDC1 gene, the region shown in SEQ ID NO: 2 in the RASSF1A gene, the region shown in SEQ ID NO: 3 in the gene, the region shown in SEQ ID NO: 4 in the gene, and the region shown in SEQ ID NO: 5 in the gene are a sequence of the CpG island in the promoter region of each gene.
[0036] Specifically, the SEQ ID NO: 1 region of the AHDC1 (Genbank accession number: NG_034158.1) gene is as follows:
[0037] GCTCTGCCCCGGCCCGGGGACTGGAGGCGCCCGGCAGCGGTCCGGA CCTGCGCTCTCGGACGCGGCTGAGTGGCGGGGTTATTAATAGCGTGCCTG GCTCGGGCAGTGGCTCCAG.
[0038] The SEQ ID NO:2 region of the RASSF1A (Genbank accession number: NG_023270.1) gene is shown below:
[0039] CCGGTTGGGGCCCGTGCTTCGCTGGCTTTGGGCGCTAGCAAGCGCGGG CCGGGCGGGGCCACAGGGCGGGCCCCGACTTCAGCGC.
[0040] The region of SEPTIN9 (Genbank accession number: NM_001113493.2) gene as shown in SEQ ID NO: 3 is as follows:
[0041] CAGCGCGCAGGGCCCGGGCCCCGCCGGGGGCGCTTCCTCGCCGCTG CCCTCCGCGCGACCCGCTGCCCACCAGCCATCATGTCGGACCCGC.
[0042] The region of the SDC2 (Genbank accession number: NM_002998.4) gene as shown in SEQ ID NO: 4 is as follows:
[0043] GAGCCCGAGTCCCCGAGCCTGAGCCGCAATCGCTGCGGTACTCTGCTCCGGATTCGTGTGCGCGGGCTGCGCCGAG.
[0044] The region of the ZNF304 (Genbank accession number: NG_051201.1) gene as shown in SEQ ID NO: 5 is as follows:
[0045] GCGTTTCCTGCTGCTCTGGGCTGCAGGGGCGAGACTTCTGGCGTCGC CGTCGTGACGTATTTTTCCTATGCCCGGTCCGTGCATTCTGGTT.
[0046] In the present invention, "CpG island" is the abbreviation of cytosine (C)-phosphate (p)-guanine (G), which refers to some regions rich in CpG dinucleotides on the genome, with a length of 300 to 3000 bp.
[0047] In some embodiments, the detection reagent of the present invention can be used to detect the methylation level of a CpG island or a sequence on a CpG island in a corresponding gene region present in a sample.
[0048] In the present invention, a "sample" is a biological sample selected from an individual, specifically, for example, selected from histological sections, tissue biopsies / paraffin-embedded tissues, and the like.
[0049] In the present invention, "detection reagent" refers to a reagent for detecting the methylation level of a gene in a sample, wherein the methylation level is measured by amplification-sequencing, chip detection, or methylation fluorescence quantitative PCR.
[0050] In some specific embodiments, the methylation level detection reagent can also be a detection reagent for detecting the average methylation level of a gene fragment.
[0051] In some specific embodiments, the methylation level detection reagent can also be a detection reagent for detecting one or more methylation sites within a gene segment.
[0052] In some specific embodiments, the detection reagents include, but are not limited to, nucleic acid primers and sequencing Tag sequences, for measuring methylation levels by amplification-sequencing.
[0053] In some specific embodiments, the detection reagent includes but is not limited to a chip, wherein the chip is a methylation chip having a probe that specifically binds to a methylation region, and the chip is used to measure the methylation level.
[0054] In some specific embodiments, the detection reagents include, but are not limited to, nucleic acid primers and nucleic acid probes for measuring methylation levels by methylation fluorescence quantitative PCR.
[0055] Furthermore, the detection reagent also includes an internal standard primer and an internal standard probe.
[0056] In a specific embodiment, the target of the internal standard primer and probe is the ACTB gene.
[0057] When the detection reagent includes nucleic acid primers and nucleic acid probes, the detection reagent detects the methylation level of nucleic acid in the sample by methylation fluorescent quantitative PCR.
[0058] In the present invention, "methylation fluorescent quantitative PCR" refers to converting the region to be detected by sulfite, and then using primers and probes specifically designed for the detection target to perform fluorescent quantitative PCR detection, thereby obtaining the methylation level of the region to be detected.
[0059] The above reagent combination may also include other reagents, specifically, for example, various reagents required for pre-treatment or pre-processing of the sample, such as a sample release agent for extracting sample nucleic acid, a purification agent for purifying sample nucleic acid, bisulfite or bisulfite used for conversion, etc.
[0060] In some specific embodiments, the detection reagents are shown in Table 1. In the following detection reagents, the upstream primer / downstream primer / probe for detecting one target corresponds to a group, and the upstream primer / downstream primer / probe for detecting the targets to be detected is used, that is, this group. Therefore, the detection reagents of the present invention can include any one or more groups of the following primers and probes.
[0061] Table 1
[0062] Primer name serial number Sequence (5'-3') ME-AHDC1-F SEQ ID NO:6 ACTCTACCCCGACCCGAAAAC ME-AHDC1-R SEQ ID NO:7 TTGGAGTTATTGTTCGAGTTAGGTACG ME-AHDC1-P SEQ ID NO:8 CCGACAACGATCCGAACCTACGCTCTC ME-RASSF1A-F SEQ ID NO:9 GCGTTGAAGTCGGGGTTCG ME-RASSF1A-R SEQ ID NO:10 CCGATTAAACCCGTACTTC ME-RASSF1A-P SEQ ID NO:11 CGCTAACAAACGCGAACCGA ME-SEPTIN9-F SEQ ID NO:15 CAACGCGCAAAACCCGAA ME-SEPTIN9-R SEQ ID NO:16 GCGGGGTTCGATATGATGGT ME-SEPTIN9-P SEQ ID NO:17 AAACGCTTCCTCGCCGCTACCCTC ME-SDC2-F SEQ ID NO:12 GAACCCGAATCCCCGAACCTA ME-SDC2-R SEQ ID NO:13 TTCGGCGTAGTTCGCGTATAC ME-SDC2-P SEQ ID NO:14 ACCGCAATCGCTACGATACTCTACTCCG ME-ZNF304-F SEQ ID NO:18 ACGTTTCCTACTACTCTAAACTACAA ME-ZNF304-R SEQ ID NO:19 AATTAGAATGTACGGATCGGGTATAG ME-ZNF304-P SEQ ID NO:20 AACTTCTAACGTCGCCGTCGTAACG
[0063] In some specific embodiments, the fluorescent channels used in the present invention are FAM, ROX, VIC and CY5 channels, but they are not limited thereto in actual application, and can be any combination of other fluorescent channels; different targets can also correspond to different fluorescent channels, such as any fluorescent channel can be used as an internal standard detection channel. Dyes such as SYBR Green can also be used for amplification.
[0064] By using the above primers and probes, a composition with a smaller Ct value, more sensitive detection, and better stability, anti-interference and precision can be obtained.
[0065] In a second aspect, the present invention provides use of the above reagent combination in preparing a kit for detecting lung cancer.
[0066] In a third aspect, the present invention provides a kit for detecting methylation genes in lung cancer, the kit comprising the reagent combination as described above.
[0067] Furthermore, the kit also includes, but is not limited to, at least one of a reagent for extracting nucleic acid, a reagent for purifying nucleic acid, and bisulfite.
[0068] Furthermore, the kit also includes a negative sample.
[0069] Specifically, the negative sample is human genomic DNA that has been sequenced to verify that there is no methylation of the target gene.
[0070] Furthermore, the kit also includes dNTPs, Mg 2+ , at least one of a methylation-sensitive restriction endonuclease, a PCR buffer, and a hot-start enzyme.
[0071] Furthermore, the range of the final concentration of each component is as follows: Mg 2+ 1~6mM, dNTPs 1~80mM, primers 0.1~40μM, probes 0.1~20μM. BRIEF DESCRIPTION OF THE DRAWINGS
[0072] Figure 1 This is an exemplary detection reagent 0.05 ng / reaction detection diagram;
[0073] Figure 2 The figure shows that there is no non-specific amplification detection in 20 ng / reaction of non-methylated DNA. DETAILED DESCRIPTION
[0074] The present invention will be described in detail below in conjunction with specific embodiments and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific embodiments and examples are used to illustrate the present invention, rather than to limit the present invention.
[0075] Example 1: Screening of methylation genes
[0076] In the early stage, a large number of blood samples were collected from cancer patients and non-cancer people. cfDNA was extracted from the plasma and treated with bisulfite for whole-genome methylation sequencing. Gene targets were found from the sequencing data, and target regions with a wide range of methylation level differences were selected. The CpG island region of the AHDC1 gene was identified as an optional detection target, and a combined model with the AHDC1 gene was further constructed for the detection of lung cancer, and its detection performance was clinically evaluated.
[0077] Example 2: Detection of gene methylation levels of standard products
[0078] Positive samples: Standard methylated human genomic DNA and target gene non-methylated human genomic DNA are mixed and configured, with a concentration of 1ng / μL containing 10% standard methylated human genomic DNA; a concentration of 1ng / μL containing 1% standard methylated human genomic DNA; a concentration of 1ng / μL containing 0.5% standard methylated human genomic DNA;
[0079] Negative samples: human genomic DNA with no target gene methylation verified by sequencing, 3ng / μL;
[0080] Testing process:
[0081] Free DNA is extracted from biological samples and treated with bisulfite, followed by PCR amplification using methylation-specific primer pairs.
[0082] PCR system configuration: Prepare PCR reaction solution according to the reagent formula in Table 3 below according to different detection targets.
[0083] Table 3
[0084] Reagent components Dosage (μL) Primer (50 μM) 0.16 Blocking primer (50 μM) 0.08 Probe (50 μM) 0.04 PCR amplification buffer 11.62 Mg ion (1M) 0.1 dNTPS (80mM) 1 Hot start enzyme (10U / μL) 1
[0085] The sample was added to the PCR reaction tube at 6 μL / reaction, and then 14 μL of PCR reaction solution was added in sequence. The PCR tube was capped, vortexed to mix, and then centrifuged for 5 seconds.
[0086] Fluorescence PCR reaction and result analysis
[0087] 1) Place the PCR reaction tube into the sample slot of the thermal amplification instrument and set the names of the samples to be tested in the corresponding order.
[0088] 2) Fluorescence detection channel selection: select the VIC channel (Reportere: VIC, Quencher: None) to detect the corresponding gene; select the CY5 channel (Reportere: CY5, Quencher: None) as the internal standard to detect the housekeeping gene ACTB;
[0089] 3) Fluorescence quantitative PCR reaction conditions are as shown in Table 4:
[0090] Table 4
[0091]
[0092] 4) Result analysis
[0093] After the reaction is finished, the instrument automatically saves the results, which can be automatically analyzed using the instrument's own software (you can also manually adjust the baseline start value, end value, and threshold line value for analysis). The intersection of the amplification curve and the threshold line is called Ct (i.e., cycle threshold, which refers to the cycle value experienced when the fluorescent signal in the PCR reaction tube reaches the set threshold). Figures 1-2 As shown, the exemplary detection reagent provided by the present invention is 0.05 ng / reaction ( Figure 1 ), no non-specific amplification in 20 ng / reaction of non-methylated DNA ( Figure 2 ).
[0094] Example 3: Effect of the composition of the present invention on detection of high-grade lung lesions and lung cancer
[0095] In order to demonstrate the detection effect of the composition of the present invention (which corresponds to the detection of SEQ ID NO.1 to 5 regions, respectively), the detection performance of different compositions of the present invention in clinical samples was compared. Marker genes were detected in peripheral blood plasma samples collected from 403 high-risk groups for lung cancer and patients with pathologically determined lung nodules or benign lung diseases or lung cancer. Different lung lesion subtypes in China were covered, including 101 patients with lung adenocarcinoma (66.01%), 37 patients with lung squamous cell carcinoma (24.18%), and 15 patients with small cell lung cancer (9.80%); 100 patients with benign lung diseases, including pneumonia, nodules, cysts, etc.; 150 normal high-risk groups, with an average age of 61 years old, with a history of smoking or passive smoking, or a family history of lung cancer, a history of occupational exposure, etc.; used to detect the composition of the present invention.
[0096] In addition to the composition of the present invention (AHDC1 gene), a multi-target joint detection system was constructed for multiple targets such as potential methylation effects on cancer, especially lung cancer, and the above samples were used to test the sensitivity and specificity of each combination and the single target of the combination of the present invention. The results showed that the clinical performance of the combination of the present invention was the best, and the results are shown in Table 4.
[0097] Table 4
[0098] Sensitivity Specificity AUC RASSF1A 85.71% 80.00% 0.857 AHDC1 88.89% 91.43% 0.936 RASSF1A+AHDC1 90.00% 93.94% 0.908 AHDC1+SEPTIN9 90.91% 91.43% 0.94 AHDC1+SEPTIN9+ZNF304 90.91% 94.29% 0.948 AHDC1+SDC2 88.89% 80.00% 0.84 AHDC1+ZNF304 85.00% 82.86% 0.84
[0099] Example 4. Stability of the composition of the present invention
[0100] The reagents (dNTP, primer, probe (nucleic acid primer and probe shown in SEQ ID NO: 6-20), solvent and polymerase) were placed at room temperature for freezing and thawing, opened the bottle, mixed, covered with a lid, placed at -20°C, and the reagent performance was tested after 2 weeks, 4 weeks, and 6 weeks. The results are shown in Table 5, the CV value is <5%, and the stability after opening the bottle is good.
[0101] Table 5
[0102] Sample 1 Ct value Sample 2 Ct value Sample 3Ct value Sample 4 Ct value Sample 5Ct value 2 weeks 29.23 29.41 29.08 29.04 29.43 4 weeks 28.97 30.33 29.07 29.12 28.58 6 weeks 28.99 29.21 28.82 28.93 28.9
[0103] The reagent was placed at -20°C for 1 hour until it was completely frozen, then taken out and placed at room temperature for 0.5 hour. After it was completely frozen and thawed, it was mixed and centrifuged. The performance of the reagent was tested after 0, 3, and 6 freeze-thaw cycles. The results are shown in Table 6. The CV value was <5%, indicating good freeze-thaw stability.
[0104] Table 6
[0105] Sample 1 Ct value Sample 2 Ct value Sample 3Ct value Sample 4 Ct value Sample 5Ct value 0 times 29.23 28.96 28.44 29.27 28.89 3 times 28.84 29.35 28.56 29.19 28.95 6 times 28.72 28.88 28.95 29.13 29.06
[0106] The reagent was placed at 37°C for 24h, 48h, and 72h, and the sample was tested with the reagent placed at -20°C to test the performance of the reagent. The results are shown in Table 7, the CV value is <5%, and the thermal stability is good.
[0107] Table 7
[0108] Sample 1 Ct value Sample 2 Ct value Sample 3Ct value Sample 4 Ct value Sample 5Ct value -20℃24h 29.07 28.99 29.07 29.04 29.01 37℃24h 29.31 29.37 29.25 29.04 29.25 -20℃48h 28.55 29.3 29.13 28.89 29.05 37℃48h 28.97 30.33 29.07 29.12 28.58 -20℃72h 28.96 29.13 28.85 29.43 29.31 37℃72h 28.98 28.99 29.48 29.16 28.82
[0109] Example 5: Anti-interference performance of the composition of the present invention
[0110] In order to verify the anti-interference property of the composition of the present invention, healthy human blood samples were added with interfering substances for experiments, including unmethylated DNA, bilirubin, hemoglobin, triglycerides, proteins, red blood cells, K2EDTA, cholesterol, uric acid and glucose, as well as common drugs. The experimental results are shown in Tables 8 to 10. It can be seen from the table that common interfering substances will not interfere with the composition of the present invention.
[0111] Table 8
[0112]
[0113] Table 9
[0114]
[0115]
[0116] Table 10
[0117]
Claims
1. A methylation marker combination for assisting the detection of lung cancer, include: The region of the AHDC1 gene as shown in SEQ ID NO:
1.
2. The methylation marker combination according to claim 1, It is characterized in that The methylation marker combination also includes at least one of the following regions: The region of the RASSF1A gene as shown in SEQ ID NO:2; The region of the SEPTIN9 gene as shown in SEQ ID NO:3; The region of the SDC2 gene as shown in SEQ ID NO:4; or The region of the ZNF304 gene as shown in SEQ ID NO:
5.
3. The methylation marker combination according to claim 2, It is characterized in that The methylation marker combination is: the region of the AHDC1 gene as shown in SEQ ID NO: 1, and the region of the RASSF1A gene as shown in SEQ ID NO: 2; the region of the AHDC1 gene as shown in SEQ ID NO: 1, and the region of the SEPTIN9 gene as shown in SEQ ID NO: 3; the region of the AHDC1 gene as shown in SEQ ID NO: 1, the region of the SEPTIN9 gene as shown in SEQ ID NO: 3, and the region of the ZNF304 gene as shown in SEQ ID NO: 5; the region of the AHDC1 gene as shown in SEQ ID NO: 1, and the region of the SDC2 gene as shown in SEQ ID NO: 4; or The region of the AHDC1 gene as shown in SEQ ID NO: 1, and the region of the ZNF304 gene as shown in SEQ ID NO:
5.
4. A detection composition for assisting the detection of lung cancer, the composition comprising a detection reagent for detecting the methylation level of the methylation marker combination according to any one of claims 1 to 3.
5. The detection composition according to claim 4, It is characterized in that The detection reagent is: Any one or more sets of nucleic acid primers and probes shown in SEQ ID NOs: 6 to 20.
6. The composition according to claim 5, It is characterized in that The composition further comprises an internal standard upstream primer, an internal standard downstream primer and an internal standard probe for monitoring.
7. Use of the composition according to any one of claims 4 to 6 in the preparation of a kit for assisting the detection of lung cancer.
8. A kit for assisting the detection of lung cancer, It is characterized in that The kit comprises the composition according to any one of claims 4 to 6.
9. The kit according to claim 8, It is characterized in that The kit further comprises at least one of a reagent for extracting nucleic acid, a reagent for purifying nucleic acid, or bisulfite.
10. The kit according to claim 9, It is characterized in that The kit also includes dNTPs, Mg 2+ , methylation-sensitive restriction endonuclease, PCR buffer, or at least one of a hot start enzyme.
Citation Information
Patent Citations
Lung cancer methylation marker, detection kit and application thereof
CN116555422A
Methylated molecular marker for lung adenocarcinoma detection, kit and application
CN117144012A
Method for detecting lung cancer using lung cancer-specific methylation marker gene
US20110027796A1
Methods and systems for diagnosis, classification, and treatment of small cell lung cancer and other high-grade neuroendocrine carcinomas
US20240150848A1
